{"created":"2023-06-19T09:11:01.564902+00:00","id":22635,"links":{},"metadata":{"_buckets":{"deposit":"10aa725d-022f-4093-85c3-5c9d3348f4a9"},"_deposit":{"created_by":1,"id":"22635","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"22635"},"status":"published"},"_oai":{"id":"oai:kumadai.repo.nii.ac.jp:00022635","sets":["415:416"]},"author_link":[],"control_number":"22635","item_16_biblio_info_6":{"attribute_name":"bibliographic_information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2009-08-21","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"959","bibliographicPageStart":"953","bibliographicVolumeNumber":"65","bibliographic_titles":[{"bibliographic_title":"Cancer Chemotherapy and Pharmacology","bibliographic_titleLang":"en"}]}]},"item_16_description_5":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"PURPOSE: This study examined the pharmacokinetics of irinotecan (CPT-11), active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38), SN-38 glucuronide (SN-38G) amrubicin (AMR), and active metabolite amrubicinol (AMR-OH) after intravenous administration of this combination therapy in rats. METHODS: Male Sprague-Dawley rats were treated with 10 mg/kg CPT-11 with 10 mg/kg AMR. AMR, AMR-OH, CPT-11, SN-38 and SN-38G were measured in plasma, bile, and tissues using high-performance liquid chromatography. RESULTS: Co-administration of CPT-11 resulted in a significant decrease in plasma concentrations and area under the curves (AUC) of AMR-OH compared with treatment with AMR alone. On the other hand, co-administration of AMR resulted in a slight increase in the initial plasma concentration of SN-38; however, there were no differences in AUC values in CPT-11 and SN-38. The cumulative biliary excretion curves of AMR, CPT-11, and their active metabolites were not changed. CPT-11 inhibited the conversion of AMR to AMR-OH in rat cytosolic fractions. CONCLUSIONS: CPT-11 did not affect the pharmacokinetic of AMR but decreased the plasma concentration of AMR-OH and might affect the formation of AMR-OH from AMR in hepatocytes.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_16_publisher_36":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer Berlin","subitem_publisher_language":"en"}]},"item_16_relation_61":{"attribute_name":"関連","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s00280-009-1102-x","subitem_relation_type_select":"DOI"}}]},"item_16_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"(C) Springer-Verlag 2009","subitem_rights_language":"en"}]},"item_16_source_id_7":{"attribute_name":"item_16_source_id_7","attribute_value_mlt":[{"subitem_source_identifier":"0344-5704","subitem_source_identifier_type":"PISSN"}]},"item_16_subject_20":{"attribute_name":"日本十進分類法","attribute_value_mlt":[{"subitem_subject":"499","subitem_subject_scheme":"NDC"}]},"item_16_version_type_19":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Maeda, Yukiko","creatorNameLang":"en"},{"creatorName":"前田, 由紀子","creatorNameLang":"ja"},{"creatorName":"マエダ, ユキコ","creatorNameLang":"ja-Kana"}]},{"creatorNames":[{"creatorName":"Hamada, Akinobu","creatorNameLang":"en"},{"creatorName":"濱田, 哲暢","creatorNameLang":"ja"},{"creatorName":"ハマダ, アキノブ","creatorNameLang":"ja-Kana"}]},{"creatorNames":[{"creatorName":"Sanematsu, Emiko","creatorNameLang":"en"},{"creatorName":"實松, 絵美子","creatorNameLang":"ja"},{"creatorName":"サネマツ, エミコ","creatorNameLang":"ja-Kana"}]},{"creatorNames":[{"creatorName":"Sasaki, Jiichiro","creatorNameLang":"en"},{"creatorName":"佐々木, 治一郎","creatorNameLang":"ja"},{"creatorName":"ササキ, ジイチロウ","creatorNameLang":"ja-Kana"}]},{"creatorNames":[{"creatorName":"Yokoo, Koji","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Hira, Asumi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Saito, Hideyuki","creatorNameLang":"en"},{"creatorName":"齋藤, 秀之","creatorNameLang":"ja"},{"creatorName":"サイトウ, ヒデユキ","creatorNameLang":"ja-Kana"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-03-02"}],"displaytype":"detail","filename":"CCP-MAEDA20090821_r.pdf","filesize":[{"value":"248.2 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"CCP-MAEDA20090821_r.pdf","url":"https://kumadai.repo.nii.ac.jp/record/22635/files/CCP-MAEDA20090821_r.pdf"},"version_id":"2e1b4467-66cc-4717-9f51-48cd1157ccd3"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Amrubicin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Amrubicinol","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Irinotecan","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Drug–drug interaction","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"item_resource_type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats","subitem_title_language":"en"}]},"item_type_id":"16","owner":"1","path":["416"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2010-09-06"},"publish_date":"2010-09-06","publish_status":"0","recid":"22635","relation_version_is_last":true,"title":["Co-administration of irinotecan decreases the plasma concentration of an active metabolite of amrubicin, amrubicinol in rats"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2024-12-27T02:50:05.519735+00:00"}